By inhibiting the Raf/MEK/ERK pathway, Sorafenib reduces angiogenesis and induces apoptosis in tumor cells [45,46], and Sorafenib-acquired resistance is associated with abnormal activation of the PI3K/AKT/mTOR pathway [47]. Here, AKT1 is linked to neoplasm.